Abstract:Abstract Background: Ceramides, glucosylceramides and sphingosine-1-phosphate (S1P) are key bioactive signaling molecules. Ceramides are proapoptotic and mitigate chemoresistance while glucosylceramides and S1P promote cancer cell proliferation, activate multiple oncogenic pathways, promote chemoresistance and stimulate a pro-tumoral microenvironment. Many studies have shown a better prognosis and longer survival for patients with high ceramides levels, while high S1P and glucosylceramides levels are associated with shorter survival and worst prognosis. Levels of ceramides, glucosylceramides and S1P are controlled by enzymes involved in sphingolipid metabolism, including glucosylcerebrosidase (Gcase) and sphingosine kinase (Sphk). Methods: BXQ-350 is a nanovesicle of Saposin C, an allosteric activator of enzymes involved in sphingolipid metabolism; preclinically, BXQ-350 was investigated in different in vitro and in vivo models. Clinically, BXQ-350 was investigated in a first-in-human Phase 1 safety dose and escalation study in cancer patients with recurrent advanced solid malignancies (NCT02859857). Results: Preclinical results demonstrated that BXQ-350 allosterically activates Gcase in vitro, in cells and in vivo in a significant and dose-dependent manner; as expected, in vivo, Gcase activation results in lower levels of glucosylceramides, as much as 2/3 lower for picomolar concentrations of BXQ-350. An increase in ceramides and a decrease in S1P are also observed. By impacting glucosylceramides, ceramides and S1P, BXQ-350 rebalances the S1P/ceramide rheostat in favor of an antitumoral state and homeostasis. By lowering S1P and glucosylceramides, BXQ-350 modulates the innate and adaptive immune response and repolarizes macrophages towards the antitumoral M1 phenotype, inhibits differentiation and activity of immunosuppressor of MDSCs, and promotes the proliferation of CD4+ and CD8+ Tcells as well as their activity. Clinical results showed BXQ-350 was safe and well-tolerated (no DLT, no MTD). Also, 13 patients (~17.8% of evaluable patients) had a clinical benefit up to cycle 6 and beyond (PR, SD). Among patients with PFS > 6 months, there were 4 recurrent CRC patients: 1 patient had a PFS of ~12 months, 2 of ~18 months, and 1 is still on study after 6 years. Furthermore, there were signs that BXQ-350 may alleviate symptoms of CIPN as 4 out of 10 patients with chronic CIPN at time of enrollment experienced an improvement of their symptoms. Conclusions: Preclinical and clinical results demonstrated that BXQ-350 activates Gcase and modulates sphingolipid metabolism leading to a novel anticancer MOA that had not been clinically tested. Additional studies are ongoing to further elucidate BXQ-350’s MOA. Citation Format: Gilles H. Tapolsky, Charlie Cruze, Robin Furnish, Michael Gazda, Timothy Stephens, Lexy Stamper, Nikhil Wilkins, Ray Takigiku. BXQ-350: A novel biologic that allosterically activates glucosylcerebrosidase and demonstrates signs of activity in cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3072.

A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

P11.03.B BXQ-350: Modulating ceramide and Sphingosine-1-Phosphate for anti-tumor activity and potential mitigation of chemotherapy induced peripheral neuropathy

BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).

Abstract 3072: BXQ-350: A novel biologic that allosterically activates glucosylcerebrosidase and demonstrates signs of activity in cancer patients

First-in-human, Phase I Study of AK109, an Anti-Vegfr2 Antibody in Patients with Advanced or Metastatic Solid Tumors

A First-in-human, Open Label, Multiple Dose, Dose Escalation, and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/metastatic HER2-expressing Solid Tumors

A First-in-human, Open-Label, Dose-Escalation and Dose-Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/pharmacodynamics, and Antitumor Activity of QL1604, a Humanized Anti–pd-1 Mab, in Patients with Advanced or Metastatic Solid Tumors

First-in-human Phase I Study of a Selective VEGFR/FGFR Dual Inhibitor Sulfatinib in Patients with Advanced Solid Tumors.

Suvemcitug As Second-Line Treatment of Advanced or Metastatic Solid Tumors and with FOLFIRI for Pretreated Metastatic Colorectal Cancer: Phase Ia/Ib Open Label, Dose-Escalation Trials

A Phase Ia/Ib Study of CBP-1008, a Bispecific Ligand Drug Conjugate, in Patients with Advanced Solid Tumors

Ctni-60. Safety Lead-In Results For Qbs10072S In The Individual Screening Trial Of Innovative Glioblastoma Therapy (Insight) Trial, A Randomized Adaptive Platform Trial For Newly Diagnosed Mgmt Unmethylated Glioblastoma

First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.

First-in-human, Phase I Study of CBP-1008, a First-in-class Bispecific Ligand Drug Conjugate (Bi-Xdc), in Patients with Advanced Solid Tumors

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of TQ-B3101.

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors

First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

Interim Results of a First-in-human Phase 1 Study of Q-1802, a CLDN18.2/PD-L1 Bsabs, in Patients with Relapsed or Refractory Solid Tumors.

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.

First-in-human Phase 1 Study of SPH4336, a Novel Cyclin-Dependent Kinase 4/6 Inhibitor, in Patients with Advanced Solid Tumors.